UPC judge and Regeneron counsel urge lobbying to improve court's transparency
Judge encourages lawyers and public to make their voices heard over transparency concerns | Awkward access to public hearings ‘causing problems’ says Regeneron counsel | Plea for public virtual hearings as judge notes that requests have been ‘coming in by the dozen’ | Panellists discuss at LSPN Europe.
EPO revokes Moderna's COVID-19 vaccine patent
The European Patent Office hands a win to BioNTech and Pfizer in coronavirus vaccine dispute | US biotech plans to appeal decision affecting mRNA patent.
10x Genomics awarded $31m in key ruling over NanoString
District court’s verdict found NanoString infringed on seven patents related to protein detection tech | Marks the third victory for 10x Genomics in the last six months | NanoString ‘must drop the charade’ says 10x CEO.
AbbVie accused of delay tactics in $1.3bn Humira dispute
Big pharma company relies on procedural arguments to fend off a complaint alleging that it engaged in excessive pricing | Feud centres on one of the most successful blockbuster drugs of all time.
Cancer specialist to pay $83.4m over DNA sequencing infringement
TwinStrand Biosciences and the University of Washington win patent infringement case related to DNA mutation technology.
Saxton & Stump adds senior tech counsel
New senior counsel joins IP group from previous roles at a Pittsburgh university, robotics company, and founding own law firm | Experience in patent prosecution in tech for life science sectors.
Neurocrine resolves dispute over Huntington's treatment
Neuroscience-focused biopharma ends litigation with four companies | Companies can introduce generic alternatives in the future.
USPTO aims to fend off Fintiv challenge at SCOTUS
Controversial rule precludes a patent review if there is parallel litigation | Big pharma and tech companies insist the rule is “arbitrary and capricious” | US agency backs Vidal’s authority, calling a proposed intervention “unnecessary”.
Taiwan company fails to overturn PTAB decision over eye treatment patent
Federal Circuit rejects appeal in patent dispute with California’s Cloudbreak Theraputics | Court stated failure to prove concrete injury.
FTC challenges more than 100 pharma patents
Commission targets big pharma companies over ‘improper listings’ | Agency argues that alleged inaccuracies may delay lower-cost generic drug competition, stall drug development, and stifle innovation.
